Research Article

Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions

Table 2

Summary of TASC lesions, distribution of diseased vessels, and interventional characteristics.

TASC II classificationEVT group (n = 94)Bypass group (n = 93) value

Aortoiliac lesions
 A16 (17.0)15 (16.3)0.225
 B11 (11.7)21 (22.8)
 C13 (13.8)11 (12.0)
 D13 (13.8)16 (17.4)
Femoropopliteal lesions
 C60 (63.8)29 (31.2)<0.001
 D34 (36.2)64 (68.8)
Infrapopliteal lesions
 B40 (42.6)42 (45.2)0.238
 C40 (42.6)30 (32.3)
 D14 (14.9)21 (22.6)
Lesion length (cm)18.5 ± 3.6 (15–29)23.4 ± 5.2 (15–33.5)<0.001
Number of distal runoffs1.78 ± 0.721.96 ± 0.790.105
1 vessel38 (40.4)31 (33.3)0.146
2 vessels40 (42.6)35 (37.6)
3 vessels16 (17.0)27 (29.0)
Stent implantation94 (100)0
BTK intervention94 (100)0
Bypass surgery093 (100)
AK FPB041 (44.1)
AK FPB plus tibial artery017 (18.3)
BK FPB023 (24.7)
BK FPB plus tibial artery12 (12.9)

AK, above the knee; BK, below the knee; DPA, dorsalis pedis artery; EVT, endovascular therapy; FPB, femoropopliteal bypass; PTA, posterior tibial artery; TASC, intersociety consensus for the management of peripheral arterial disease.